Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 44,805 restricted stock units (RSUs) to 20 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025. The RSUs were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultra-rare genetic diseases, announced that CFO and Executive VP Howard Horn will participate in a fireside chat at Bank of America's 2025 Healthcare Conference. The event is scheduled for Tuesday, May 13, 2025, at 8:00 a.m. PT. Investors and interested parties can access both the live and archived webcast of the panel through Ultragenyx's investor relations website.
Ultragenyx Pharmaceutical (NASDAQ: RARE), a leading biopharmaceutical company specializing in rare and ultra-rare genetic diseases, has scheduled its first quarter 2025 financial results conference call.
The earnings call will take place on Tuesday, May 6, 2025, at 5:00 p.m. ET. During this call, the company will present its financial performance for the quarter ending March 31, 2025, along with a corporate update.
Investors and interested parties can access the live webcast through the company's investor relations website at https://ir.ultragenyx.com/events-presentations. A replay of the conference call will remain available for three months following the presentation.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 36,831 restricted stock units to 21 newly hired non-executive officers. The awards were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on April 16, 2025.
The stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for new hires.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 21,806 restricted stock units to 16 newly hired non-executive officers. The awards, approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan on March 16, 2025, serve as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultrarare genetic diseases, has announced its participation in three major investor conferences in March 2025.
The company's Chief Medical Officer, Dr. Eric Crombez, will represent Ultragenyx at:
- The 45th Annual Cowen Healthcare Conference in Boston on March 3
- The Barclays 27th Annual Global Healthcare Conference in Miami on March 11
- The Leerink Partners Global Biopharma Conference in Miami on March 12
At each event, Dr. Crombez will participate in a fireside chat and conduct one-on-one meetings. Investors can access live and archived webcasts of the fireside chats through Ultragenyx's investor relations website.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 23,760 restricted stock units to 10 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025. The grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), serve as employment inducements for the new hires.
The restricted stock units have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced FDA acceptance of their Biologics License Application (BLA) for UX111, an AAV gene therapy targeting Sanfilippo syndrome type A (MPS IIIA). The FDA granted Priority Review with a PDUFA date of August 18, 2025, and indicated no current plans for an advisory committee meeting.
The BLA submission is supported by data from the pivotal Transpher A and long-term follow-up studies presented at WORLDSymposium™ 2025. Results showed rapid and sustained decreases in heparan sulfate levels in cerebrospinal fluid, with statistically significant improvements in Bayley-III scores for cognition and communication compared to untreated patients. Treatment-related adverse events were primarily mild to moderate liver enzyme elevations that resolved.